Sector Watch: Healthcare - Mar 21 2019
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $111.97 -1.21 -1.07% | XBI: $91.92 +1.59 1.76% | Updated Mar 21, 2019 04:26 PM
HEALTHCARE STOCKS - TOP GAINERS | ||||
---|---|---|---|---|
SRNE Sorrento Therapeutics $639.5M |
5.23+1.74 15.6 M 7.0x |
50% | ||
PRAN Prana Biotechnology $1.1B |
2.04+0.30 274.5 K 3.2x |
17% | ||
VKTX Viking Therapeutics $668.0M |
9.28+1.01 5.5 M 1.7x |
12% | ||
ZSAN Zosano Pharma $64.1M |
5.35+0.57 2.2 M |
12% | ||
OPK Opko Health Inc $1.7B |
2.72+0.26 9.7 M 1.7x |
11% |
HEALTHCARE STOCKS - TOP LOSERS | ||||
---|---|---|---|---|
BIIB52WL Biogen $44.6B |
226.88-93.71 20.7 M 17.2x |
-29% | ||
CVRS Corindus Vascular Robotics $379.4M |
1.84-0.54 7.1 M 6.4x |
-23% | ||
CHMA Chiasma $123.1M |
5.03-1.17 344.4 K 2.8x |
-19% | ||
LQDA Liquidia Technologies $173.6M |
11.15-2.54 1.2 M 18.4x |
-19% | ||
CYTK Cytokinetics $485.2M |
8.84-1.35 2.2 M 3.2x |
-13% |
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer?s Disease [globenewswire.com]2019 Partners HealthCare World Medical Innovation Forum [globenewswire.com]
Liquidia Technologies Announces Pricing of Offering of Common Stock [globenewswire.com]
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer?s Disease Nasdaq:BIIB [globenewswire.com]
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis [globenewswire.com]
Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistry, Manufacturing and Controls (CMC) [globenewswire.com]
Liquidia Technologies Announces Proposed Offering of Common Stock [globenewswire.com]
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19 [globenewswire.com]
ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results [globenewswire.com]
Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm [globenewswire.com]
Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference [globenewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.